Ibrutinib, a Bruton ’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity

Approximately 15 million people, including 8% of children, in the United States have food allergy and are at risk of having life-threatening anaphylactic reactions.1 There is an unmet need for the prevention of such reactions. Tyrosine kinases, including Bruton's tyrosine kinase (BTK), have been shown to be critical for allergen reactivity by transducing Fc εRI crosslinking signals into cellular activation and mediator release from mast cells and basophils.2 Pharmacyclics, Inc, together with Janssen Pharmaceuticals, recently received Food and Drug Administration approval of ibrutinib (Imbruvica, PCI-32765) as a selective, irreversible BTK inhibitor fo r the treatment of mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and Waldenstrom's macroglobulinemia.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Letter to the Editor Source Type: research